BIvideocpd7

Name:

Surname:

MP Number:

Email address:

Contact number:

Question 1
True or false: RE-LY® excluded patients who were scheduled for cardioversion

a) True

b) False

Question 2
How many cardioversions were performed in the RE-LY® study?

a) 1345

b) 1270

c) 1983

d) 1110

Question 3
What percentage of patients in the RE-LY® study received dabigatran for at least 3 weeks before cardioversion?

a) 79.2-85.5 %

b) 76.4-79.2 %

c) 85.5-92.1 %

d) 65.1-72.3 %

Question 4
What percentage of patients in the RE-LY® study received warfarin for at least 3 weeks before cardioversion?

a) 79.2 %

b) 76.4 %

c) 85.5 %

d) 92.1 %

Question 5
What is the major reason for anticoagulation before cardioversion?

a) To prevent thrombus formation in the right atrium

b) To improve outcomes of cardioversion

c) To prevent cerebral stroke

d) All of the above

Question 6
Which statement regarding transoesophageal echocardiogram (TEE) is incorrect?

a) It can cause complications

b) Patients need to be hospitalised for TEE

c) Patients may need an anaesthetic for TEE

d) Was performed in more patients receiving warfarin than dabigatran in the RE-LY® study

Question 7
What was the difference in the rates of stroke/SE for dabigatran vs. warfarin among patients undergoing AF conversion in the RE-LY® study?

a) No significant difference

b) Increased with dabigatran

c) Decreased with dabigatran

d) Not evaluated

Question 8
What was the difference in the rates of major bleeding for dabigatran vs. warfarin among patients undergoing AF conversion in the RE-LY® study?

a) No significant difference

b) Increased with dabigatran

c) Decreased with dabigatran

d) Not evaluated

Question 9
What was the difference in the rates of stroke/SE for dabigatran vs. warfarin between patients with and without TEE before cardioversion in the RE-LY® study?

a) No significant difference

b) Increased with dabigatran

c) Decreased with dabigatran

d) Not evaluated